Jefferies Financial Group Inc. Takes Position in Masimo Co. (NASDAQ:MASI)

Jefferies Financial Group Inc. purchased a new stake in Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 10,657 shares of the medical equipment provider's stock, valued at approximately $1,762,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Forum Financial Management LP acquired a new position in shares of Masimo during the 4th quarter worth about $217,000. Pacific Point Advisors LLC acquired a new stake in Masimo during the 4th quarter valued at $208,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Masimo by 69.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 190,246 shares of the medical equipment provider's stock valued at $31,448,000 after buying an additional 77,775 shares during the last quarter. Woodline Partners LP grew its stake in Masimo by 450.4% in the 4th quarter. Woodline Partners LP now owns 51,185 shares of the medical equipment provider's stock valued at $8,461,000 after buying an additional 41,885 shares during the last quarter. Finally, Tidal Investments LLC grew its position in shares of Masimo by 3,530.4% in the fourth quarter. Tidal Investments LLC now owns 86,731 shares of the medical equipment provider's stock valued at $14,337,000 after purchasing an additional 84,342 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on MASI. BTIG Research set a $193.00 target price on Masimo and gave the company a "buy" rating in a research report on Wednesday, May 7th. Raymond James decreased their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating and issued a $200.00 target price (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Wells Fargo & Company decreased their target price on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Finally, Wall Street Zen lowered shares of Masimo from a "buy" rating to a "hold" rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Masimo presently has an average rating of "Moderate Buy" and an average target price of $191.60.

Masimo Price Performance

Shares of Masimo stock traded up $4.39 on Friday, reaching $161.36. 1,085,666 shares of the stock were exchanged, compared to its average volume of 649,664. The firm's 50 day moving average is $157.13 and its 200-day moving average is $167.24. Masimo Co. has a one year low of $101.61 and a one year high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm has a market cap of $8.75 billion, a PE ratio of 111.28 and a beta of 1.23.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. During the same quarter in the prior year, the firm posted $0.77 EPS. The firm's quarterly revenue was down 24.5% on a year-over-year basis. As a group, analysts anticipate that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Transactions at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares of the company's stock, valued at $4,048,568.28. This represents a 55.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. The trade was a 11.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,053 shares of company stock valued at $6,998,565. Company insiders own 9.70% of the company's stock.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.